Page 75 - Demo

Methylphenidate for ADHD in Smith-Magenis syndrome73322. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015. 23. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertility and Sterility. 2018. 24. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. Journal of Clinical Epidemiology. 2011. 25. Tate RL, Perdices M. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. 2019. 26. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988.27. Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015.28. OCEBM Levels of Evidence Working Group, Durieux N, Pasleau F, Howick J. The Oxford 2011 Levels of Evidence. Group. 2011.29. Porcino AJ, Shamseer L, Chan AW, Kravitz RL, Orkin A, Punja S, et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ. 2020.30. Mitchell GK, Hardy JR, Nikles CJ, Carmont SAS, Senior HE, Schluter PJ, et al. The effect of methylphenidate on fatigue in advanced cancer: An aggregated N-of-1 trial. J Pain Symptom Manage. 2015.31. Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. In: Behavioural Brain Research. 2002. 32. Mazefsky CA, Yu L, White SW, Siegel M, Pilkonis PA. The emotion dysregulation inventory: Psychometric properties and item response theory calibration in an autism spectrum disorder sample. Autism Res. 2018.33. Gaasterland CMW, Van Der Weide MCJ, Roes KCB, Van Der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: A conceptual proposal for validation. BMC Med Res Methodol. 2019.34. Elliott R, Wagner J, Sales CMD, Rodgers B, Alves P, Café MJ. Psychometrics of the personal questionnaire: A client-generated outcome measure. Psychol Assess. 2016.35. Goodman R, Meltzer H, Bailey V. The Strengths and Difficulties Questionnaire: A pilot study on the validity of the self-report version. International Review of Psychiatry. 2003. 36. Mazefsky CA, Yu L, Pilkonis PA. Psychometric Properties of the Emotion Dysregulation Inventory in a Nationally Representative Sample of Youth. J Clin Child Adolesc Psychol. 2020.37. Hall CL, Guo B, Valentine AZ, Groom MJ, Daley D, Sayal K, et al. The validity of the Strengths and Difficulties Questionnaire (SDQ) for children with ADHD symptoms. PLoS One. 2019.38. Kaptein S, Jansen DEMC, Vogels AGC, Reijneveld SA. Mental health problems in children with intellectual disability: Use of the Strengths and Difficulties Questionnaire. J Intellect Disabil Res. 2008.39. Tate RL, Perdices M, Rosenkoetter U, Wakim D, Godbee K, Togher L, et al. Revision of a method quality rating scale for single-case experimental designs and n-of-1 trials: The 15-item Risk of Bias in N-of-1 Trials (RoBiNT) Scale. Neuropsychol Rehabil. 2013.40. Methylphenidate (MPH): physician’s guide to prescribing [Internet]. [cited 2021 Mar 9]. Available from: www.methylphenidate-guide.eu.41. Senn S. Sample size considerations for n-of-1 trials. Stat Methods Med Res. 2019.42. Matthijssen AFM, Dietrich A, Bierens M, Kleine Deters R, Van De Loo-Neus GHH, Van Den Hoofdakker BJ, et al. Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress. J Child Adolesc Psychopharmacol. 2020.43. Muris P, Meesters C, Van den Berg F. The Strengths and Difficulties Questionnaire (SDQ) further evidence for its reliability and validity in a community sample of Dutch children and adolescents. Eur Child Adolesc Psychiatry. 2003.44. m-Path [Internet]. [cited 2021 Mar 9]. Available from: www.m-Path.io.Annelieke Muller sHL.indd 73 14-11-2023 09:07